Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02826603 · ClinicalTrials.gov registry record · Phase 3
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,114
- Enrollment target
NCT02826603: Completed Phase 3 study, sponsored by Novartis Pharmaceuticals.
NCT02826603 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,114 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (44% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02826603, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,114 participants
- Enrollment target
Study Summary
Demonstrate superiority of secukinumab over ustekinumab in treatment of moderate to severe plaque psoriasis.
Primary Outcome
Number of participants who achieved ≥ 90% reduction in PASI compared to baseline. Logistic regression analysis of PASI 90 response at Week 12 PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, upper limbs, trunk, lower limbs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%),
Interventions
- DRUG Ustekinumab
- DRUG Secukinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,114 participants |
| Start Date | 2016-06-22 |
| Est. Completion | 2018-07-09 |
| Phase | Phase 3 |
What the finished NCT02826603 record still lists
NCT02826603 is an interventional study that assigns participants to a tested intervention. Its 1,114 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (44% higher).
The record links to 0 conditions, and to 2 interventions - of which Ustekinumab is the first listed.
NCT02826603 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02826603 about?
NCT02826603 is a clinical study titled "Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis". Demonstrate superiority of secukinumab over ustekinumab in treatment of moderate to severe plaque psoriasis.
What is the current status of trial NCT02826603?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,114 participants. The study started on 2016-06-22. Estimated completion is 2018-07-09.
What interventions are being tested in trial NCT02826603?
The interventions under investigation include: Ustekinumab (DRUG), Secukinumab (DRUG).
Who is sponsoring clinical trial NCT02826603?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02826603's enrollment target sits among peer trials
1,114 251st of 2000 higher than 1,750 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02140255 · 1,120 participants · Phase 1
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
- NCT06618534 · 1,120 participants · Phase 2
Azithromycin for Meningococcal Carriage
- NCT07164131 · 1,120 participants · Phase 4
Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lactams
- NCT05691478 · 1,122 participants · Phase 2
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI